{"id":"NCT01970475","sponsor":"Amgen","briefTitle":"Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis","officialTitle":"A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2014-11","completion":"2014-11","firstPosted":"2013-10-28","resultsPosted":"2016-12-13","lastUpdate":"2016-12-13"},"enrollment":526,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"BIOLOGICAL","name":"ABP 501","otherNames":["AMJEVITA™","Adalimumab-atto"]},{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["HUMIRA®"]}],"arms":[{"label":"ABP 501","type":"EXPERIMENTAL"},{"label":"Adalimumab","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the effectiveness and safety of ABP 501 against adalimumab (HUMIRA®) in adults with moderate to severe rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX).","primaryOutcome":{"measure":"Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"ABP 501","deltaMin":74.6,"sd":null},{"arm":"Adalimumab","deltaMin":72.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["United States","Canada","Germany","United Kingdom"]},"refs":{"pmids":["33263165","28584187"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":264},"commonTop":["Nasopharyngitis"]}}